MFDS
- Marketing authorisation holder: LANTHEUS
- Status: likely_approved
🇰🇷 Neuraceq in South Korea
Neuraceq (FLORBETABEN) regulatory status in South Korea.
Marketing authorisation
Neuraceq in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in South Korea
Frequently asked questions
Is Neuraceq approved in South Korea?
Yes. MFDS has authorised it.
Who is the marketing authorisation holder for Neuraceq in South Korea?
LANTHEUS holds the South Korean marketing authorisation.